Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2019

View Archived Issues

beta-1,4-GalT-V as a novel diagnostic and therapeutic biomarker in human CRC

Healthy people with afflicted parents give insight into AD genetics

Autologous exosomes deliver chemotherapy

E. coli toxin produced in unexpected ways

Enrollment ongoing in first-in-human study of PBF-1650

Brown University and Bryant University describe new antibacterials

Meiji Seika Pharma, Kaken Pharmaceutical patent nuclear receptor RORgamma antagonists

Mirati Therapeutics initiates phase I/II study of MRTX-849

2-Acylglycerol O-acyltransferase 2 inhibitors identified at Shionogi

Phase II trial of varlitinib in advanced gastric cancer does not meet primary endpoint

Novartis presents lysine-specific histone demethylase 1A inhibitors

New multitargeted PARP, PI3K and/or BRD4 inhibitors disclosed by SignalRx Pharmaceuticals

Hampton University, the University of Virginia describe labeled thymidine compounds

Verona reports topline data from 3-day phase II study of ensifentrine for COPD

Alnylam explores ALN-AAT02 in phase I/II study for ZZ type AAT deficiency liver disease

Researchers elucidate link between miR-377 and atherosclerosis

New Kv7 potassium channel openers show promise for epilepsy

EpicentRx begins phase III trial of RRx-001 prior to platinum doublet in small cell carcinoma

Bioverativ begins phase I/II study of BIVV-003 in sickle cell disease

New study to investigate DKN-01 in DKK1-positive metastatic castration-resistant prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...